BACKGROUND AND AIM: With the development of immunology, the role of immune inflammation in idiopathic pulmonary arterial hypertension (IPAH) has attracted interest. Recently, it was discovered that dendritic cells, which are key players in immune inflammation, are implicated in the pathogenesis of IPAH. To elucidate the role of dendritic cells in human IPAH, we compared the changes in the number and immunological function of monocyte-derived dendritic cells (MoDCs) from the peripheral blood of patients with IPAH and healthy controls. METHODS: The numbers of MoDC subsets (including plasmacytoid dendritic cells (pDCs) and myeloid dendritic cells (mDCs)) in circulating peripheral blood mononuclear cells (PBMCs) was analyzed by flow cytometry, and the concentrations of interleukin (IL)-12, IL-10, and tumor necrosis factor-alpha were measured by enzyme-linked immunosorbent serologic assay kits. The morphology, phenotypic expression, and the ability to stimulate T cell proliferation of MoDCs, cultured from PBMCs in vitro with granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-4, was analyzed by microscopy, flow cytometry, and MTT assay. RESULTS: The results of the study are as follows: (1) The number of circulating mDCs was lower in IPAH patients than in controls (0.07 +/- 0.01% to 0.14 +/- 0.02%; p < 0.05). (2) IL-12 levels were higher in IPAH patients than in controls (p < 0.05). (3) MoDCs showed higher expression of CD1a (53.34 +/- 7.43% to 19.29 +/- 7.37%; p < 0.05), and lower expression of costimulatory molecule CD86 (64.54 +/- 5.93% to 87.04 +/- 4.82%; p < 0.05), and less ability to simulate T cell proliferation (when the ratio is 1:10) compared to the controls. CONCLUSIONS: The study shows that it is possible to obtain typical DCs by culturing PBMCs from patients with IPAH with GM-CSF and IL-4, and it demonstrates that patients with IPAH have a significant change in the number of mDC and a marked immune deficiency of MoDCs.
BACKGROUND AND AIM: With the development of immunology, the role of immune inflammation in idiopathic pulmonary arterial hypertension (IPAH) has attracted interest. Recently, it was discovered that dendritic cells, which are key players in immune inflammation, are implicated in the pathogenesis of IPAH. To elucidate the role of dendritic cells in human IPAH, we compared the changes in the number and immunological function of monocyte-derived dendritic cells (MoDCs) from the peripheral blood of patients with IPAH and healthy controls. METHODS: The numbers of MoDC subsets (including plasmacytoid dendritic cells (pDCs) and myeloid dendritic cells (mDCs)) in circulating peripheral blood mononuclear cells (PBMCs) was analyzed by flow cytometry, and the concentrations of interleukin (IL)-12, IL-10, and tumor necrosis factor-alpha were measured by enzyme-linked immunosorbent serologic assay kits. The morphology, phenotypic expression, and the ability to stimulate T cell proliferation of MoDCs, cultured from PBMCs in vitro with granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-4, was analyzed by microscopy, flow cytometry, and MTT assay. RESULTS: The results of the study are as follows: (1) The number of circulating mDCs was lower in IPAH patients than in controls (0.07 +/- 0.01% to 0.14 +/- 0.02%; p < 0.05). (2) IL-12 levels were higher in IPAH patients than in controls (p < 0.05). (3) MoDCs showed higher expression of CD1a (53.34 +/- 7.43% to 19.29 +/- 7.37%; p < 0.05), and lower expression of costimulatory molecule CD86 (64.54 +/- 5.93% to 87.04 +/- 4.82%; p < 0.05), and less ability to simulate T cell proliferation (when the ratio is 1:10) compared to the controls. CONCLUSIONS: The study shows that it is possible to obtain typical DCs by culturing PBMCs from patients with IPAH with GM-CSF and IL-4, and it demonstrates that patients with IPAH have a significant change in the number of mDC and a marked immune deficiency of MoDCs.
Authors: Atilla Yilmaz; Jana Weber; Iwona Cicha; Christian Stumpf; Michael Klein; Dieter Raithel; Werner G Daniel; Christoph D Garlichs Journal: J Am Coll Cardiol Date: 2006-06-12 Impact factor: 24.094
Authors: Rebecca Bowers; Carlyne Cool; Robert C Murphy; Rubin M Tuder; Matthew W Hopken; Sonia C Flores; Norbert F Voelkel Journal: Am J Respir Crit Care Med Date: 2003-12-30 Impact factor: 21.405
Authors: S Rich; D R Dantzker; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; S K Koerner Journal: Ann Intern Med Date: 1987-08 Impact factor: 25.391
Authors: Michael E Yeager; Cecilia M Nguyen; Dmitry D Belchenko; Kelley L Colvin; Shinichi Takatsuki; D Dunbar Ivy; Kurt R Stenmark Journal: Chest Date: 2011-09-22 Impact factor: 9.410
Authors: Denise van Uden; Thomas Koudstaal; Jennifer A C van Hulst; Madelief Vink; Menno van Nimwegen; Leon M van den Toorn; Prewesh P Chandoesing; Annemien E van den Bosch; Mirjam Kool; Rudi W Hendriks; Karin A Boomars Journal: Int J Mol Sci Date: 2022-06-10 Impact factor: 6.208
Authors: Laura C Price; Gaetano Caramori; Frederic Perros; Chao Meng; Natalia Gambaryan; Peter Dorfmuller; David Montani; Paolo Casolari; Jie Zhu; Konstantinos Dimopoulos; Dongmin Shao; Barbara Girerd; Sharon Mumby; Alastair Proudfoot; Mark Griffiths; Alberto Papi; Marc Humbert; Ian M Adcock; S John Wort Journal: PLoS One Date: 2013-10-04 Impact factor: 3.240